FDA re­jects blad­der can­cer ther­a­py de­vel­oped by Patrick Soon-Sh­iong’s Im­mu­ni­ty­Bio

The FDA re­ject­ed Im­mu­ni­ty­Bio’s bi­o­log­ics li­cense ap­pli­ca­tion for a spe­cif­ic blad­der can­cer, and the biotech’s shares $IBRX tum­bled about 50% be­fore the open­ing bell Thurs­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER